Advanced and Metastatic Cervical Cancer
Conditions
Interventions
test group:Bevacizumab combined with paclitaxel and cisplatin (TP) triple therapy
Sponsors
Shenshan Medical Center, Memorial Hospital of Sun Yat-Sen University
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients aged between 18 and 65 years old; Pathological diagnosis of cervical squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma before any treatment; The patients of FIGO stage Ib3-IIA2 cervical cancer with Lymph vascular space invasion (LVSI) or IIb-IVb, the depth of tumor invasion is more than 1/2 of the cervical muscle layer, the lymph vessel is positive, the maximum diameter of tumor is >= 5cm, and the diameter of tumor is less than 5cm. Pelvic or para-aortic lymph nodes were positive.
Exclusion criteria
Exclusion criteria: (1) other tumors (2) previous chemotherapy or radiotherapy prior to the study (3) other contraindications to radiotherapy, or chemotherapy (4) any renal, hepatic, respiratory, cardiac, or psychiatric disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival,OS;Progression free survival,PFS; | — |
Countries
China
Contacts
Public ContactYongpai Peng
Shenshan Medical Center, Memorial Hospital of Sun Yat-Sen University
Outcome results
None listed